Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...

The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

CHMP recommends approval of Roche’s Tecentriq as first-line monotherapy treatment for people with type of metastatic NSCLC: Basel Saturday, March 27, 2021, 11:00 Hrs [IST] Roche ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the ...